Yurong Peng,Zhuo Li,Yucheng Fu,Y. Pan,Yanjun Zeng,Junqi Liu,Chaoyue Xiao,Yingze Zhang,Yahui Su,Guoqing Li,Fang Wu

Abstract:Missing Supplementary Material In the published article, Supplementary two figures was mistakenly not included in the publication. We would like to put Figure 1 in the end of the part of Introduction and Figure 2 in the end of the part of the Discussion. The missing material appears below:The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Corrigendum: Immune regulation and prognostic prediction model establishment and validation of PSMB6 in lung adenocarcinoma

Corrigendum: Development and validation of a m6A -regulated prognostic signature in lung adenocarcinoma

Corrigendum: Construction and Validation of a Lung Cancer Risk Prediction Model for Non-Smokers in China

Corrigendum: Comprehensive analysis of the prognostic and immunological role of PAFAH1B in pan-cancer

Corrigendum: LASSO-derived prognostic model predicts cancer-specific survival in advanced pancreatic ductal adenocarcinoma over 50 years of age: a retrospective study of SEER database research

Corrigendum: A Prognostic Model Based on Immune-Related Long Non-Coding RNAs for Patients With Cervical Cancer

Corrigendum: Validation of the GALAD model and establishment of a new model for HCC detection in Chinese patients

Corrigendum: Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis

Corrigendum: ASPM is a prognostic biomarker and correlates with immune infiltration in kidney renal clear cell carcinoma and liver hepatocellular carcinoma

Corrigendum: Identification of an immune-related gene prognostic index for predicting survival and immunotherapy efficacy in papillary renal cell carcinoma

Corrigendum: NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis

Corrigendum: Establishment and Validation of Prognostic Nomograms for Patients with Parotid Gland Adenocarcinoma Not Otherwise Specified: a SEER Analysis from 2004 to 2016.

Corrigendum: Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer

Corrigendum: Identification and validation of immune-related methylation clusters for predicting immune activity and prognosis in breast cancer

Corrigendum to “system Analysis of ROS-Related Genes in the Prognosis, Immune Infiltration, and Drug Sensitivity in Hepatocellular Carcinoma”

Corrigendum: Long non-coding RNA AL139385.1 as a novel prognostic biomarker in lung adenocarcinoma

Corrigendum: Identification and Validation of Novel Biomarkers for Diagnosis and Prognosis of Hepatocellular Carcinoma

Corrigendum to “Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis”

Correction: Corrigendum: IL-17 Promotes Angiogenic Factors IL-6, IL-8, and Vegf Production Via Stat1 in Lung Adenocarcinoma

Corrigendum: MXD3 as an Immunological and Prognostic Factor From Pancancer Analysis

Corrigendum to “ARMCX Family Gene Expression Analysis and Potential Prognostic Biomarkers for Prediction of Clinical Outcome in Patients with Gastric Carcinoma”